Clinical
GLP-1 Microdosing: What the Evidence Actually Says
A commercial category, not a clinical one. Here's what that means for you.
"Microdosing" GLP-1s is a commercial category, not a clinical one — it has no standardized definition and no trial base for sub-therapeutic weight-loss dosing. This piece separates what the marketing implies from what the evidence actually supports.
There is no standard definition
Unlike the approved products' studied doses, "microdose" has no agreed clinical meaning. Different providers use it for different regimens, generally implying a dose below the therapeutic range studied in the pivotal trials. Because the term isn't standardized, two "microdose" programs may not be comparable to each other, let alone to the approved-product evidence. The first thing to understand is that you're looking at a marketing label, not a defined clinical protocol.
The evidence gap
The weight-loss results people cite for GLP-1s — the ~15% in STEP-1 for semaglutide, the ~20%+ in SURMOUNT-1 for tirzepatide — come from trials at specific therapeutic doses. A deliberately sub-therapeutic "microdose" was not what those trials tested, so their outcomes don't transfer to it. There isn't a comparable trial base establishing what a microdose achieves for weight management. That doesn't mean microdosing does nothing; it means its effect for this purpose is unestablished, which is a different and weaker claim than the marketing suggests.
Why lower doses cost less — and what that isn't
Microdose programs price lower because they supply less medication, not because they're a proven discount on a proven treatment. A lower microdose price reflects a smaller dose whose weight-loss benefit isn't established — so the apparent savings can be illusory if the regimen doesn't produce the outcome you're paying for. Comparing a microdose price against a standard-dose price as if they were the same product is a category error; they're different products with different (and, for microdose, uncertain) expected effects.
How we treat microdose figures
| Dimension | Standard therapeutic dose | "Microdose" |
|---|---|---|
| Definition | Specific studied doses | No standardized definition |
| Weight-loss trial base | STEP-1, SURMOUNT-1 | None comparable |
| Lower price reflects | — | Less medication, not proven value |
On this site, microdose and standard-dose programs are never merged into one ranking, and microdose pricing is shown separately with an explicit note that the lower price reflects a smaller dose, not a proven better value. Whether a microdose regimen is appropriate for you is a clinical question for a prescriber, not a shopping decision — and it's one where the honest answer is that the evidence is thin.
Primary sources
This article's regulatory and safety statements draw on the following primary sources from the U.S. Food and Drug Administration:
Frequently asked questions
Does GLP-1 microdosing work for weight loss?
That isn't established. The weight-loss evidence comes from trials at specific therapeutic doses, not from sub-therapeutic microdoses, and there's no comparable trial base for microdosing as a weight-management strategy. It may do something, but its effect for this purpose is uncertain — a weaker claim than marketing implies. It's a clinical question for a prescriber.
Is a microdose plan cheaper?
It's cheaper per month because it supplies less medication, not because it's a proven discount on the same result. If the smaller dose doesn't produce the outcome you want, the savings are illusory. Compare microdose against microdose, never against standard-dose, and treat the lower price as reflecting a smaller (and less-evidenced) dose.
Why don't you rank microdose plans with standard-dose plans?
Because they're different products with different expected effects, and microdosing has no standardized definition or equivalent evidence base. Merging them into one ranking would imply a comparability that doesn't exist. We show microdose pricing separately with an explicit evidence caveat.
Evidence status. Pricing figures are provider-reported or independently calculated as of 2026-07-20, not checkout-verified. Compounded medications are not FDA approved. This article is consumer education, not medical advice. See the methodology for how figures are gated and the public evidence ledger for per-figure sources. Found an error? Use the corrections route.